CATTANEO, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 98
AS - Asia 42
EU - Europa 30
SA - Sud America 5
Totale 175
Nazione #
US - Stati Uniti d'America 97
SG - Singapore 24
DE - Germania 8
CN - Cina 7
VN - Vietnam 6
BR - Brasile 5
RU - Federazione Russa 5
IE - Irlanda 4
AT - Austria 2
FR - Francia 2
GB - Regno Unito 2
HK - Hong Kong 2
IT - Italia 2
UA - Ucraina 2
CA - Canada 1
FI - Finlandia 1
HR - Croazia 1
KR - Corea 1
PH - Filippine 1
RS - Serbia 1
TR - Turchia 1
Totale 175
Città #
Singapore 19
Fairfield 10
Wilmington 8
Houston 7
Ashburn 6
Dong Ket 6
Seattle 6
Woodbridge 6
Dearborn 5
Beijing 4
Boardman 4
Dublin 4
Princeton 4
Cambridge 3
Düsseldorf 3
Hong Kong 2
Jacksonville 2
Los Angeles 2
Ogden 2
Udine 2
Ann Arbor 1
Chandler 1
Frankfurt am Main 1
Guangzhou 1
Izmir 1
Joinville 1
London 1
Manila 1
Munich 1
New York 1
Nova Serrana 1
Nuremberg 1
Ottawa 1
Philadelphia 1
Porto Alegre 1
Porto Seguro 1
San Diego 1
Seoul 1
Sumaré 1
Turku 1
Zagreb 1
Totale 126
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 85
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 30
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 30
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 28
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 20
Totale 193
Categoria #
all - tutte 1.292
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.292


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 1 0
2020/202127 3 1 0 2 0 4 6 2 1 1 0 7
2021/202215 0 1 0 0 0 0 1 0 0 4 5 4
2022/202310 4 0 0 0 0 4 0 0 2 0 0 0
2023/202416 2 1 0 3 1 0 0 2 2 0 1 4
2024/202572 4 7 5 1 4 4 7 6 14 8 12 0
Totale 193